Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma

Value in Health

Volumn 13, Issue 1, 2010, Pages 55-60

  Hoyle, Martin ^a   Green, Colin ^a   Thompson Coon, Jo ^a   Liu, Zulian ^a   Welch, Karen ^b   Moxham, Tiffany ^a   Stein, Ken ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Cost effectiveness; Cost utility; Decision analytic modeling; Nexavar; Renal cell carcinoma; Sorafenib

Indexed keywords

SORAFENIB;

ADVANCED CANCER; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

EID: 72949111671     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00616.x     Document Type: Article

References (25)

1. Thompson-coon J, Hoyle M, Green C, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. In press.
2. Cancer Statistics Registrations. Registrations of cancer diagnosed in 2004, England. Report No.: Series MB1 no.35. 2006.
3. WCISU Annual Publication. Cancer incidence in Wales 2000-2004. Welsh Cancer Intelligence and Surveillance Unit. Report No.: No. SA 6/01. 2006.
4. NICE. Renal cell carcinoma-bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation document. London : National Institute for Health and Clinical Excellence, 2008.
5. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007 356 : 125 134.
6. NICE. Guide to the Methods of Technology Appraisal. London : National Institute for Health and Clinical Excellence, 2008.
7. Billingham LJ, Abrams KR, Jones DR. Methods for the analysis of quality-of-life and survival data in health technology assessment. Health Technol Assess 1999 3 : 42.
8. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006 24 : 16 24.
9. Remak E, Charbonneau C, Negrier S, et al. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol 2008 26 : 3995 4000.
10. NICE. Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation document 2. 2009. Available from: http://www.nice.org.uk/guidance/index.jsp?action=article&o=41473 [Accessed September 11, 2009].
11. Curtis L. Unit Costs of Health and Social Care 2007. Canterbury, UK : Personal Social Services Research Unit, 2007.
12. National Cancer Institute (NCI). Common Toxicity Criteria (CTC) Version 2.0. Bethesda, MD : National Cancer Institute (NCI), 1999.
13. National Institute for Health and Clinical Excellence. NICE clinical guideline 34: national cost impact report to accompany 'Hypertension: the management of hypertension in adults in primary care (partial update)'. 2006.
14. Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation (1st ed.). New York : Oxford University Press, 2006.
15. Mason H, Jones-Lee M, Donaldson C. Modelling the monetary value of a QALY: a new approach based on UK data. Health Econ 2009 18 : 933 950.
16. Towse A, Pritchard C, Devlin N. Cost-effectiveness Thresholds. Economic and Ethical Issues. London : Office of Health Economics, 2002.
17. WHO. Cost-effectiveness Thresholds. Geneva : World Health Organization, 2008.
18. NICE. Appraising Orphan Drugs. London : National Institute for Health and Clinical Excellence, 2006.
19. Collett D. Modelling Survival Data in Medical Research (2nd ed.). Boca Raton, FL : Chapman & Hall/CRC, 2003.
20. Department of Health. NHS reference costs 2006-07. 2008. Available from: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-082571 [Accessed September 11, 2009].
21. Department of Health. NHS reference costs 2005-06. 2006. Available from: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-062884 [Accessed September 11, 2009].
22. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary 57. 2009. Available from: http://www.bnf.org/bnf/extra/current/450035.htm [Accessed June 1, 2009].
23. Remak E, Brazil L Cost of managing women presenting with stage IV breast cancer in the United Kingdom. Br J Cancer 2004 91 : 77 83.
24. Coyle D, Small N, Ashworth A, et al. Costs of palliative care in the community, in hospitals and in hospices in the UK. Crit Rev Oncol Hematol 1999 32 : 71 85.
25. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 356 : 115 124. (Pubitemid 46089672)